LexaGene Holdings Inc. announced earnings results for the third quarter ended November 30, 2019. For the third quarter, the company announced net loss was USD 2.530 million compared to USD 2.254 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. For the nine months, net loss was USD 5.819 million compared to USD 6.150 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.1 a year ago.